AbbVie Reports Strong Financial Performance
AbbVie Inc. (NYSE: ABBV) recently announced its impressive third-quarter sales, reaching $15.78 billion, which surpassed analysts' expectations of around $15.59 billion. This remarkable achievement reflects a 9.1% increase on a reported basis and 8.4% on an operational basis. The company also reported adjusted earnings of $1.86 per share, which, despite a decrease of 38%, still managed to exceed the anticipated $1.79.
Dividend Increase Reflects Confidence
In a notable move, AbbVie increased its quarterly dividend from $1.64 to $1.73 per share. Robert Michael, the chairman and CEO, expressed satisfaction with the company's continued progress, stating that they are making great strides in advancing their pipeline and investing in innovation to support AbbVie's long-term growth strategy. This increase in dividends signifies AbbVie’s robust performance and optimistic outlook.
Immunology Sales Drive Revenue Growth
Immunology Portfolio Success
AbbVie’s immunology portfolio was a significant contributor, generating global net revenues of $7.89 billion, marking an 11.9% increase. Key performers in this segment included Skyrizi and Rinvoq, which saw respective sales increases of 46.8% and 35.3%, generating $4.71 billion and $2.18 billion. Contrarily, Humira experienced a decline, with sales dropping 55.4% to $993 million.
Oncology and Neuroscience Portfolio Performance
While the oncology portfolio generated $1.68 billion in sales, which is down slightly, it included revenues of $706 million from Imbruvica, a drop of 14.8%. Venclexta, however, showed a slight increase of 7.1%, contributing $726 million, and Elahere recorded $170 million in revenue.
As for the neuroscience portfolio, it showcased a sale increase of 20.2%, totaling $2.84 billion. Noteworthy growth was seen in Vraylar, generating $934 million, while Botox Therapeutics contributed $985 million.
Outlook for Fiscal Year 2025
AbbVie has revised its fiscal 2025 earnings guidance, now estimating an adjusted earnings per share range of $10.61 to $10.65 compared to the previous $10.38 to $10.58. This is against a consensus forecast of $10.53 per share. However, it is important to note that this guidance incorporates an unfavorable impact of $2.05 per share due to acquired IPR&D and milestone expenses incurred year-to-date.
Analyst Insights on AbbVie’s Future
Industry analyst William Blair emphasizes that AbbVie’s key franchises in immunology and inflammation are exceeding expectations and presenting upside potential for overall revenue growth. In the mid- to long-term, significant drivers of growth are anticipated from the company's Parkinson’s disease franchise, including Vyalev and tavapadon, along with a promising late-stage antibody-drug conjugate portfolio.
Currently, AbbVie shares are trading at 15.8 times the 2026 consensus EPS, indicating they may be undervalued considering the company's strong growth profile. William Blair continues to hold an Outperform rating on the stock.
Current Stock Performance
As of the latest update, ABBV stock has seen a 3.70% decline, bringing the price down to $219.76. Despite this fluctuation, the overall growth outlook and strong financial performance indicate a positive trajectory for AbbVie.
Frequently Asked Questions
What were AbbVie's reported sales for the third quarter?
AbbVie reported third-quarter sales of $15.78 billion.
How much is AbbVie's new quarterly dividend?
AbbVie increased its quarterly dividend to $1.73 per share.
What drove AbbVie’s revenue growth?
Revenue was primarily driven by the success of the immunology portfolio, particularly Skyrizi and Rinvoq.
What is the new earnings guidance for fiscal year 2025?
AbbVie has raised its adjusted earnings guidance to a range of $10.61 to $10.65 per share.
How is the stock currently performing?
ABBV stock recently traded down by 3.70%, with the price at $219.76.
